Literature DB >> 23142300

Seasonal influenza vaccine efficacy and its determinants in children and non-elderly adults: a systematic review with meta-analyses of controlled trials.

Carlos A DiazGranados1, Martine Denis, Stanley Plotkin.   

Abstract

CONTEXT: The true level of influenza vaccine efficacy is controversial and many factors may influence its estimation.
OBJECTIVES: To estimate the efficacy of vaccination of children and non-elderly adults for the prevention of influenza and to explore the impact of type of vaccine, age, degree of strain matching, influenza type and case ascertainment methods on vaccine efficacy estimates. DATA SOURCES: Medline and EmBase databases until October 2011. References of relevant articles were also reviewed. STUDY SELECTION: Controlled trials evaluating seasonal influenza vaccines and presenting incidence of laboratory-confirmed influenza illness were eligible. Studies exploring efficacy after experimental challenge, presenting duplicate data, employing group randomization, or focusing on special populations were excluded. DATA EXTRACTION: The vaccine effect on influenza prevention was evaluated by calculating Mantel-Haenszel risk ratios (RR) and using random-effects models. Vaccine efficacies were calculated for each comparison as (1-RR)×100.
RESULTS: Thirty studies were included in one or more of a total of 101 analyses, comprising 88.468 study participants. There was evidence of heterogeneity in 49% of the analyses. Summary vaccine efficacy was 65% against any strain, 78% against matched strains and 55% against not-matched strains. Both live-attenuated and inactivated vaccines showed similar levels of protection against not-matched strains (60% and 55%, respectively). Live-attenuated vaccines performed better than inactivated vaccines in children (80% versus 48%), whereas inactivated vaccines performed better than live-attenuated vaccines in adults (59% versus 39%). There was a large difference (20%) in efficacy against influenza A (69%) and influenza B (49%) types for not-matched strains. Summary estimates of vaccine efficacy were highest when ascertainment was based on culture confirmation.
CONCLUSION: Influenza vaccines are efficacious, but efficacy estimates depend on many variables including type of vaccine and age of vaccinees, degree of matching of the circulating strains to the vaccine, influenza type, and methods of case ascertainment.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23142300     DOI: 10.1016/j.vaccine.2012.10.084

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  54 in total

1.  Genetic measurement of memory B-cell recall using antibody repertoire sequencing.

Authors:  Christopher Vollmers; Rene V Sit; Joshua A Weinstein; Cornelia L Dekker; Stephen R Quake
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-29       Impact factor: 11.205

2.  Changing face of vaccination in immunocompromised hosts.

Authors:  Daire O'Shea; Lukas A Widmer; Jörg Stelling; Adrian Egli
Journal:  Curr Infect Dis Rep       Date:  2014-09       Impact factor: 3.725

3.  Cost-effectiveness analysis of universal influenza vaccination with quadrivalent inactivated vaccine in the United States.

Authors:  Karen M Clements; Genevieve Meier; Lisa J McGarry; Narin Pruttivarasin; Derek A Misurski
Journal:  Hum Vaccin Immunother       Date:  2014-03-07       Impact factor: 3.452

4.  Simultaneous Targeting of Multiple Hemagglutinins to APCs for Induction of Broad Immunity against Influenza.

Authors:  Ane Marie Anderson; Marta Baranowska-Hustad; Ranveig Braathen; Gunnveig Grodeland; Bjarne Bogen
Journal:  J Immunol       Date:  2018-02-02       Impact factor: 5.422

5.  Induction of IL21 in Peripheral T Follicular Helper Cells Is an Indicator of Influenza Vaccine Response in a Previously Vaccinated HIV-Infected Pediatric Cohort.

Authors:  Lesley R de Armas; Nicola Cotugno; Suresh Pallikkuth; Li Pan; Stefano Rinaldi; M Celeste Sanchez; Louis Gonzalez; Alberto Cagigi; Paolo Rossi; Paolo Palma; Savita Pahwa
Journal:  J Immunol       Date:  2017-01-27       Impact factor: 5.422

Review 6.  Vaccine approaches conferring cross-protection against influenza viruses.

Authors:  Sai V Vemula; Ekramy E Sayedahmed; Suryaprakash Sambhara; Suresh K Mittal
Journal:  Expert Rev Vaccines       Date:  2017-09-19       Impact factor: 5.217

7.  Influenza vaccine response profiles are affected by vaccine preparation and preexisting immunity, but not HIV infection.

Authors:  Christoph T Berger; Victor Greiff; Matthias Mehling; Stefanie Fritz; Marc A Meier; Gideon Hoenger; Anna Conen; Mike Recher; Manuel Battegay; Sai T Reddy; Christoph Hess
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

8.  Influenza vaccination in children primed with MF59-adjuvanted or non-adjuvanted seasonal influenza vaccine.

Authors:  Timo Vesikari; Aino Forstén; Ashwani Arora; Theodore Tsai; Ralf Clemens
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

9.  The Interleukin-33-Group 2 Innate Lymphoid Cell Axis Represents a Potential Adjuvant Target To Increase the Cross-Protective Efficacy of Influenza Vaccine.

Authors:  Clare M Williams; Sreeja Roy; Danielle Califano; Andrew N J McKenzie; Dennis W Metzger; Yoichi Furuya
Journal:  J Virol       Date:  2021-09-01       Impact factor: 5.103

10.  The Split Virus Influenza Vaccine rapidly activates immune cells through Fcγ receptors.

Authors:  William E O'Gorman; Huang Huang; Yu-Ling Wei; Kara L Davis; Michael D Leipold; Sean C Bendall; Brian A Kidd; Cornelia L Dekker; Holden T Maecker; Yueh-Hsiu Chien; Mark M Davis
Journal:  Vaccine       Date:  2014-09-06       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.